Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2000 2
2001 1
2002 2
2003 1
2005 2
2008 3
2009 4
2010 4
2011 3
2012 1
2013 1
2014 2
2015 1
2016 1
2017 4
2018 3
2019 2
2020 2
2021 3
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic factors in follicular lymphoma.
Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Relander T, et al. J Clin Oncol. 2010 Jun 10;28(17):2902-13. doi: 10.1200/JCO.2009.26.1693. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385990 Review.
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators. Wulf GG, et al. Among authors: relander t. Leukemia. 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5. Epub 2020 May 7. Leukemia. 2021. PMID: 32382083 Clinical Trial.
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, Do YR, Mun YC, Lee SR, Shin HJ, Suh C, Chuang SS, Lee YS, Lim ST, Izutsu K, Suzuki R, Relander T, d'Amore F, Schmitz N, Jaccard A, Kim WS. Kwong YL, et al. Among authors: relander t. Ann Oncol. 2018 Jan 1;29(1):256-263. doi: 10.1093/annonc/mdx684. Ann Oncol. 2018. PMID: 29077846 Free article.
Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Ludvigsen Al-Mashhadi A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, Bjerregård Pedersen M, Bech Mortensen T, Relander T, Jerkeman M, Ortved Gang A, Kristensen AL, Roost Clausen M, de Nully Brown P, Tang Severinsen M, Jakobsen LH, Ellin F, El-Galaly TC. Ludvigsen Al-Mashhadi A, et al. Among authors: relander t. Am J Hematol. 2023 Mar;98(3):388-397. doi: 10.1002/ajh.26803. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588403 Free article.
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod HE. d'Amore F, et al. Among authors: relander t. J Clin Oncol. 2012 Sep 1;30(25):3093-9. doi: 10.1200/JCO.2011.40.2719. Epub 2012 Jul 30. J Clin Oncol. 2012. PMID: 22851556 Clinical Trial.
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.
Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ. Ellin F, et al. Among authors: relander t. Br J Haematol. 2019 Aug;186(3):e24-e27. doi: 10.1111/bjh.15859. Epub 2019 Mar 11. Br J Haematol. 2019. PMID: 30859549 Free PMC article. No abstract available.
45 results